U.S. markets close in 6 hours 30 minutes
  • S&P 500

    3,818.43
    -1.29 (-0.03%)
     
  • Dow 30

    31,321.58
    +51.49 (+0.16%)
     
  • Nasdaq

    12,956.62
    -41.13 (-0.32%)
     
  • Russell 2000

    2,207.79
    -23.72 (-1.06%)
     
  • Crude Oil

    62.34
    +1.06 (+1.73%)
     
  • Gold

    1,713.70
    -2.10 (-0.12%)
     
  • Silver

    26.08
    -0.31 (-1.16%)
     
  • EUR/USD

    1.2038
    -0.0029 (-0.24%)
     
  • 10-Yr Bond

    1.4790
    +0.0090 (+0.61%)
     
  • GBP/USD

    1.3970
    +0.0018 (+0.13%)
     
  • USD/JPY

    107.4480
    +0.4460 (+0.42%)
     
  • BTC-USD

    49,660.73
    -2,149.49 (-4.15%)
     
  • CMC Crypto 200

    996.69
    +9.48 (+0.96%)
     
  • FTSE 100

    6,646.51
    -28.96 (-0.43%)
     
  • Nikkei 225

    28,930.11
    -628.99 (-2.13%)
     

eHealth, Inc.'s (NASDAQ:EHTH) Share Price Is Still Matching Investor Opinion Despite 26% Slump

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

The eHealth, Inc. (NASDAQ:EHTH) share price has fared very poorly over the last month, falling by a substantial 26%. The recent drop completes a disastrous twelve months for shareholders, who are sitting on a 56% loss during that time.

In spite of the heavy fall in price, given close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 21x, you may still consider eHealth as a stock to avoid entirely with its 33x P/E ratio. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's so lofty.

eHealth could be doing better as its earnings have been going backwards lately while most other companies have been seeing positive earnings growth. One possibility is that the P/E is high because investors think this poor earnings performance will turn the corner. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.

Check out our latest analysis for eHealth

pe
pe

Want the full picture on analyst estimates for the company? Then our free report on eHealth will help you uncover what's on the horizon.

What Are Growth Metrics Telling Us About The High P/E?

eHealth's P/E ratio would be typical for a company that's expected to deliver very strong growth, and importantly, perform much better than the market.

If we review the last year of earnings, dishearteningly the company's profits fell to the tune of 40%. That put a dampener on the good run it was having over the longer-term as its three-year EPS growth is still a noteworthy 27% in total. Although it's been a bumpy ride, it's still fair to say the earnings growth recently has been mostly respectable for the company.

Turning to the outlook, the next three years should generate growth of 86% each year as estimated by the eleven analysts watching the company. That's shaping up to be materially higher than the 16% each year growth forecast for the broader market.

In light of this, it's understandable that eHealth's P/E sits above the majority of other companies. Apparently shareholders aren't keen to offload something that is potentially eyeing a more prosperous future.

The Final Word

Even after such a strong price drop, eHealth's P/E still exceeds the rest of the market significantly. Generally, our preference is to limit the use of the price-to-earnings ratio to establishing what the market thinks about the overall health of a company.

As we suspected, our examination of eHealth's analyst forecasts revealed that its superior earnings outlook is contributing to its high P/E. At this stage investors feel the potential for a deterioration in earnings isn't great enough to justify a lower P/E ratio. Unless these conditions change, they will continue to provide strong support to the share price.

It is also worth noting that we have found 4 warning signs for eHealth (1 is concerning!) that you need to take into consideration.

It's important to make sure you look for a great company, not just the first idea you come across. So take a peek at this free list of interesting companies with strong recent earnings growth (and a P/E ratio below 20x).

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.